Altimmune (ALT) Current Assets (2010 - 2026)
Altimmune (ALT) posted quarterly Current Assets of $334.7 million for Q1 2026, up 115.56% year-over-year from $155.3 million in Q1 2025, and up 20.3% quarter-over-quarter from $278.2 million in Q4 2025.
Altimmune (ALT) Current Assets (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Current Assets for 17 consecutive years, with $334.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 115.56% year-over-year to $334.7 million; the TTM figure through Mar 2026 stood at $334.7 million (up 115.56% YoY), while the FY2025 annual figure was $278.2 million, up 102.68% from the prior year.
- Current Assets grew to $334.7 million in Q1 2026 per ALT's latest filing, from $278.2 million in the prior quarter.
- Across five years, Current Assets topped out at $334.7 million in Q1 2026 and bottomed at $137.3 million in Q4 2024.
- Historically, Current Assets has averaged $194.7 million across 5 years, with a median of $188.4 million in 2025.
- Annual changes were most pronounced in 2024 — Current Assets plunged 34.52% — and 2026, when it jumped 115.56%.
- Altimmune's Current Assets stood at $192.8 million in 2022, then climbed by 8.72% to $209.6 million in 2023, then slumped by 34.52% to $137.3 million in 2024, then jumped by 102.68% to $278.2 million in 2025, then climbed by 20.3% to $334.7 million in 2026.
- Business Quant data shows ALT's Current Assets at $334.7 million in Q1 2026, $278.2 million in Q4 2025, and $216.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - | 334.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 334.82 Mn |
| Mar 31, 2026 | 334.68 Mn |
| Dec 31, 2025 | 278.19 Mn |
| Sep 30, 2025 | 216.62 Mn |
| Jun 30, 2025 | 188.42 Mn |
| Mar 31, 2025 | 155.26 Mn |
| Dec 31, 2024 | 137.25 Mn |
| Sep 30, 2024 | 145.76 Mn |
| Jun 30, 2024 | 171.19 Mn |
| Mar 31, 2024 | 187.52 Mn |
| Dec 31, 2023 | 209.63 Mn |
| Sep 30, 2023 | 152.96 Mn |
| Jun 30, 2023 | 169.53 Mn |
| Mar 31, 2023 | 173.11 Mn |
| Dec 31, 2022 | 192.81 Mn |
| Sep 30, 2022 | 211.00 Mn |
| Jun 30, 2022 | 195.50 Mn |
| Mar 31, 2022 | 191.09 Mn |
| Dec 31, 2021 | 204.13 Mn |
| Sep 30, 2021 | 218.26 Mn |